The aim of the study was to evaluate the effect of an active metabolite of losartan - EXP3174 - on a performed venous thrombus in hypertensive rat. The contribution of coagulation and fibrinolytic systems as well as platelets in the EXP3174 action was also determined. Male Wistar rats with renovascular hypertension (2K1C) were used in the study. Stasis-induced venous thrombus was allowed to age for 7 hours before intravenous injection of EXP3174 (10 mg/kg and 30 mg/kg). Thrombus reduction was then evaluated as the difference in thrombus weight 1 hour after drug or its vehiculum administration (8 h-aged thrombus). Euglobulin clot lysis time (ECLT), overall hemostasis potential (OHP), overall coagulation potential (OCP), the time to fibrin generation (TFG), and thrombin amidolytic activity were measured in blood. Collagen-induced platelet aggregation was measured in whole blood. Bleeding time (BT) and systolic blood pressure (SBP) were measured 1 hour after drug administration. EXP3174 in hypotensive doses caused a marked, dose-dependent decrease in venous thrombus weight. Shortened ECLT and decreased OCP, OHP and thrombin amidolytic activity were also observed. Platelet aggregation was significantly decreased after a higher dose of EXP3174, while no changes in BT were observed. Our study provides evidence for reduction of the weight of a formed venous thrombus by losartan metabolite - EXP3174 - in the mechanism involving enhancement of plasma fibrinolytic activity as well as reduced platelet reactivity and coagulation inhibition in 2K1C hypertensive rats.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.26402/jpp.2019.3.11 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy of Tranexamic Acid in General Surgery.
JAMA Surg
January 2025
Population Health Research Institute, Hamilton, Ontario, Canada.
Importance: Perioperative bleeding is common in general surgery. The POISE-3 (Perioperative Ischemic Evaluation-3) trial demonstrated efficacy of prophylactic tranexamic acid (TXA) compared with placebo in preventing major bleeding without increasing vascular outcomes in noncardiac surgery.
Objective: To determine the safety and efficacy of prophylactic TXA, specifically in general surgery.
Effect of plasma levels of factor VIII according to procoagulant phospholipids on the risk of future venous thromboembolism.
Res Pract Thromb Haemost
January 2025
Thrombosis Research Group, Department of Clinical Medicine, UiT - The Arctic University of Norway, Tromsø, Norway.
Background: A high level of plasma coagulation factor (F)VIII is an established and likely causal risk factor for venous thromboembolism (VTE). Procoagulant phospholipids (PPLs) facilitate FVIII activity in coagulation.
Objectives: To assess the association between plasma levels of FVIII and risk of future VTE according to PPL clotting time (PPL), an inverse surrogate measure of plasma PPL activity.
Validation of the 5-SNP score for the prediction of venous thromboembolism in a Danish fast-track cohort of 6789 total hip and total knee arthroplasty patients.
Res Pract Thromb Haemost
January 2025
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Background: Venous thromboembolism (VTE) is a serious complication following total hip arthroplasty (THA) and total knee arthroplasty (TKA). Despite improvements with fast-track treatment protocols, 0.5% of patients still develop a VTE within 90-days postoperatively.
View Article and Find Full Text PDFAcquired factor V inhibitor in a case of pediatric venous thrombosis.
Res Pract Thromb Haemost
January 2025
Department of Pediatric Hematology, Innovative Hematology, Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
Background: The development of acquired factor (F)V with inhibitor (AFVwI) is rare, resulting mainly in bleeding complications, although sporadic cases of thrombosis in adults have been reported.
Key Clinical Question: How do you diagnose and manage a pediatric case of acute deep venous thrombosis associated with the concurrent finding of AFVwI?
Clinical Approach: A 13-year-old female with Crohn's Disease and May-Thurner anatomy developed extensive deep venous thrombosis of the left lower extremity, complicated by the finding of AFVwI, discovered during the evaluation of a prolonged prothrombin time and a low FV activity. Anticoagulation was initiated with low-molecular-weight heparin followed by a direct oral anticoagulant, rivaroxaban, without any complications.
High levels of soluble P-selectin, neutrophil extracellular traps, and myeloperoxidase as risk factor of deep vein thrombosis in malignancy patients receiving platinum-based chemotherapy.
F1000Res
January 2025
Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Udayana University, Denpasar, Bali, 80113, Indonesia.
Backgrounds: Venous Thromboembolism (VTE) is a disease entity comprising Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). VTE events increase the mortality rate of patients with cancer receiving platinum-based chemotherapy. Soluble P-Selectin, Neutrophil Extracellular Traps (NET), and myeloperoxidase (MPO) are risk factors associated with DVT in malignancy patients receiving platinum-based chemotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!